Prostate Cancer

Improving prostate cancer detection with Professor of Urology Antti Rannikko at Helsinki University Hospital.

Globally, an alarming 1.4 million new prostate cancer cases are diagnosed each year, but the actual number of cases is likely higher due to the significant number of undiagnosed cases. While countless men face the challenge of undiagnosed and untreated prostate cancer, tens of thousands of others undergo unnecessary treatment for non-lethal forms of the disease.

The existing prostate cancer screening tests are limited in their ability to accurately identify lethal forms of the disease. This leads to false positive results, as well as missed diagnoses of aggressive cases. This disparity in outcomes highlights the need for better screening methods to improve patient care. Detecting potentially lethal prostate cancer variants (Grade Groups 4 and 5) in an early phase is one of the most important objectives for prostate cancer screening.

Our peer-reviewed research studies and respective scientific publications show that AQ Biotech’s biosensors can accurately screen and classify the lethal types of prostate cancer from urine samples – a long-awaited accomplishment in prostate cancer detection.